Viewing Study NCT03620669


Ignite Creation Date: 2025-12-24 @ 10:58 PM
Ignite Modification Date: 2026-01-03 @ 11:05 PM
Study NCT ID: NCT03620669
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-08-15
First Post: 2018-07-03
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: 1st Line Durvalumab in PS 2 NSCLC Patients
Sponsor: Swiss Cancer Institute
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module